Drugs / CMV Immune globulin
CMV Immune globulin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00000584 | Jul 1983 → Jun 1988 | cytomegalovirus infection | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00214240 | Jan 2000 → Apr 2007 | cytomegalovirus infection | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV immune globulin | “Lots of high titer CMV immune globulin suitable for intravenous administration were prepared using a technique of screening outdated blood bank plasma for units with high...” NCT00000584 ↗ |
| Known as | CMV-immune globin | “To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin (CMVIG) to immunize high risk premature infants against CMV infections.” NCT00000584 ↗ |
| Known as | CMVIG | “To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin (CMVIG) to immunize high risk premature infants against CMV infections.” NCT00000584 ↗ |
| Route | Intravenous | “intravenously administered” NCT00000584 ↗ |